$MGNX
MACROGENICS INC Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000112534520000072 Filed on May 05, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$13.68M	$9.662M
YoY Change	41.61%	105.79%
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$13.68M
YoY Change
Gross Profit Margin	100.0%
Selling, General & Admin	$10.20M	$10.20M
YoY Change	0.0%	10.87%
% of Gross Profit	74.55%
Research & Development	$48.89M	$47.06M
YoY Change	3.9%	3.04%
% of Gross Profit	357.36%
Depreciation & Amortization	$3.079M	$2.903M
YoY Change	6.06%	116.97%
% of Gross Profit	22.5%
Operating Expenses	$48.89M	$47.06M
YoY Change	3.9%	3.04%
Operating Profit	-$45.45M	-$47.62M
YoY Change	-4.56%	-5.16%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$721.0K	$2.600M
YoY Change	-72.27%	285.76%
Pretax Income	-$44.70M	-$45.00M
YoY Change	-0.67%	-9.09%
Income Tax
% Of Pretax Income
Net Earnings	-$44.72M	-$45.02M
YoY Change	-0.65%	-9.12%
Net Earnings / Revenue	-326.88%	-465.92%
Basic Earnings Per Share
Diluted Earnings Per Share	-$912.2K	-$986.8K
COMMON SHARES
Basic Shares Outstanding	48.98M shares	48.78M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$170.8M	$320.4M
YoY Change	-46.69%	23.18%
Cash & Equivalents	$93.06M	$238.6M
Short-Term Investments	$77.80M	$81.80M
Other Short-Term Assets	$12.60M	$8.500M
YoY Change	48.24%	136.11%
Inventory
Prepaid Expenses	$12.63M	$8.309M
Receivables	$11.81M	$6.115M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$195.3M	$335.0M
YoY Change	-41.71%	23.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.32M	$54.82M
YoY Change	-15.51%	2.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$23.81M	$24.79M
YoY Change	-3.94%	1453.07%
Total Long-Term Assets	$70.13M	$79.61M
YoY Change	-11.91%	44.63%
TOTAL ASSETS
Total Short-Term Assets	$195.3M	$335.0M
Total Long-Term Assets	$70.13M	$79.61M
Total Assets	$265.4M	$414.6M
YoY Change	-35.99%	27.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.956M	$925.0K
YoY Change	111.46%	-90.99%
Accrued Expenses	$25.06M	$28.85M
YoY Change	-13.14%	-5.37%
Deferred Revenue	$9.506M	$18.09M
YoY Change	-47.44%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$39.61M	$51.77M
YoY Change	-23.49%	3.63%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$515.0K	$42.30M
YoY Change	-98.78%	46.88%
Total Long-Term Liabilities	$515.0K	$42.30M
YoY Change	-98.78%	46.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.61M	$51.77M
Total Long-Term Liabilities	$515.0K	$42.30M
Total Liabilities	$74.84M	$94.02M
YoY Change	-20.4%	19.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$686.8M	-$535.3M
YoY Change	28.31%	67.9%
Common Stock	$877.3M	$855.9M
YoY Change	2.5%	39.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$190.6M	$320.6M
YoY Change
Total Liabilities & Shareholders Equity	$265.4M	$414.6M
YoY Change	-35.99%	27.16%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$44.72M	-$45.02M
YoY Change	-0.65%	-9.12%
Depreciation, Depletion And Amortization	$3.079M	$2.903M
YoY Change	6.06%	116.97%
Cash From Operating Activities	-$44.14M	-$30.00M
YoY Change	47.14%	-4.15%
INVESTING ACTIVITIES
Capital Expenditures	$1.253M	$1.675M
YoY Change	-25.19%	-88.46%
Acquisitions
YoY Change
Other Investing Activities	$11.82M	-$68.82M
YoY Change	-117.18%	-302.95%
Cash From Investing Activities	$10.56M	-$70.49M
YoY Change	-114.99%	-463.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$118.7M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$162.0K	$119.0M
YoY Change	-99.86%	18789.68%
NET CHANGE
Cash From Operating Activities	-$44.14M	-$30.00M
Cash From Investing Activities	$10.56M	-$70.49M
Cash From Financing Activities	$162.0K	$119.0M
Net Change In Cash	-$33.42M	$18.51M
YoY Change	-280.5%	-264.12%
FREE CASH FLOW
Cash From Operating Activities	-$44.14M	-$30.00M
Capital Expenditures	$1.253M	$1.675M
Free Cash Flow	-$45.40M	-$31.68M
YoY Change	43.31%	-30.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001125345
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49131150	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48958763	shares
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-36112
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	MACROGENICS, INC.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1591613
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	9704 Medical Center Drive
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2020Q1	dei	City Area Code CityAreaCode	301
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	251-5172
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2020Q1	dei	Trading Symbol TradingSymbol	MGNX
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49138017	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93056000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126472000	USD
CY2020Q1	us-gaap	Investments Investments	77793000	USD
CY2019Q4	us-gaap	Investments Investments	89284000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11806000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12744000	USD
CY2020Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12630000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11285000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	195285000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	239785000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46318000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48211000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23810000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24505000	USD
CY2020Q1	us-gaap	Assets Assets	265413000	USD
CY2019Q4	us-gaap	Assets Assets	312501000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1956000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4308000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25060000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27139000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9506000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10700000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3088000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3020000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	39610000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45167000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	8100000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9153000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26615000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27553000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	515000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q1	us-gaap	Liabilities Liabilities	74840000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	81873000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	492000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	490000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	876815000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	872204000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	72000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	16000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-686806000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-642082000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	190573000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	230628000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	265413000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	312501000	USD
CY2020Q1	us-gaap	Revenues Revenues	13682000	USD
CY2019Q1	us-gaap	Revenues Revenues	9662000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48894000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47060000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10233000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10219000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	59127000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	57279000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-45445000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-47617000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	721000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2600000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-44724000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-45017000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	56000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44668000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45014000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.91
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.99
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49012663	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45606651	shares
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	230628000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4451000	USD
CY2020Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	162000	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	56000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-44724000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	190573000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	242877000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3750000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	118657000	USD
CY2019Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	347000	USD
CY2019Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-45017000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	320617000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-44724000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-45017000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2809000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2903000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4491000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3799000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-938000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-23468000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1345000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1902000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-695000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2079000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-2286000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-2531000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2118000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4297000	USD
CY2020Q1	mgnx	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-869000	USD
CY2019Q1	mgnx	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	1086000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2248000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5430000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	515000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44142000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30000000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	61186000	USD
CY2019Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	81597000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	73003000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	12780000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1253000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1675000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10564000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70492000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	118657000	USD
CY2020Q1	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	162000	USD
CY2019Q1	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	348000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	162000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	119005000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33416000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	18513000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126472000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220128000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93056000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	238641000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1988000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	77721000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	99000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	27000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	77793000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	89268000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	26000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	89284000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4491000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3799000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6706994	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.33
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1403627	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.49
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	172387	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.94
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	293295	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	18.97
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7644939	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.95
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1185000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4358640	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	23.05
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1184000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7306954	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	21.04
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1185000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.12
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.65
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1100000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1600000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	300000	USD
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3700000	USD
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3100000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	33000000.0	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D

Files In Submission

Name	View Source	Status
0001125345-20-000072-index-headers.html	Edgar Link	pending
0001125345-20-000072-index.html	Edgar Link	pending
0001125345-20-000072.txt	Edgar Link	pending
0001125345-20-000072-xbrl.zip	Edgar Link	pending
exhibit31-1q12020.htm	Edgar Link	pending
exhibit31-2q12020.htm	Edgar Link	pending
exhibit32-1q12020.htm	Edgar Link	pending
exhibit32-2q12020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgnx-033120x10xqexhibi.htm	Edgar Link	pending
mgnx-20200331.htm	Edgar Link	pending
mgnx-20200331.xsd	Edgar Link	pending
mgnx-20200331_cal.xml	Edgar Link	unprocessable
mgnx-20200331_def.xml	Edgar Link	unprocessable
mgnx-20200331_htm.xml	Edgar Link	completed
mgnx-20200331_lab.xml	Edgar Link	unprocessable
mgnx-20200331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MACROGENICS INC Stock $mgnx

2020 Q1 Form 10-Q Financial Statement

#000112534520000072 Filed on May 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MACROGENICS INC Stock $mgnx

2020 Q1 Form 10-Q Financial Statement

#000112534520000072 Filed on May 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MACROGENICS INC Stock $mgnx